Microbiological and clinical characteristics of Streptococcus pneumoniae serotype 3 infection and risk factors for severe outcome: A multicenter observational study

J Microbiol Immunol Infect. 2023 Jun;56(3):598-604. doi: 10.1016/j.jmii.2023.01.013. Epub 2023 Feb 2.

Abstract

Background/purpose: Serotype 3 has persisted to be an important cause of invasive pneumococcal disease in adults in the post-vaccine era. We aimed to investigate clinical and microbiological characteristics of Streptococcus pneumoniae serotype 3 infection in Taiwan and identify the risk factors associated with severe clinical outcome.

Methods: A multicenter observational study was conducted to analyze serotype 3 isolates collected between 2012 and 2021. Demographics, comorbidities, and risk categories were statistically compared with clinical outcome. Antimicrobial susceptibility testing and multilocus sequence typing were performed.

Results: A total of 146 isolates were collected, including 12 isolates regarded as colonizers. Among 134 infected cases, 54 (40.3%) were aged 65 and older. Mortality was significantly associated with diabetes mellitus, immunosuppression, immunodeficiency, high-risk status, and older age. Susceptibility rates were high to levofloxacin (98.9%), moxifloxacin (100%), vancomycin (100%), and ceftriaxone (97.3%). 25.3% (37/146) of the isolates showed intermediate susceptibility and 0.7% (1/146) showed resistance to penicillin. ST180 was the dominant sequence type. ST13 and ST9625 isolates were less susceptible to penicillin and ceftriaxone.

Conclusions: Serotype 3 infection showed a high mortality rate, especially in patients with older ages and comorbidities. Although the incidence rates decreased during the COVID-19 pandemic, serotype 3 remained as an important cause of infection after the implementation of PCV13. Developing a more effective vaccine against serotype 3 and monitoring the antimicrobial-resistant sequence types are necessary.

Keywords: Antimicrobial susceptibility; Mortality; Prognosis; Sequence type; Serotype 3; Streptococcus pneumoniae.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Adult
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents*
  • COVID-19* / epidemiology
  • Ceftriaxone
  • Humans
  • Microbial Sensitivity Tests
  • Multilocus Sequence Typing
  • Pandemics
  • Penicillins
  • Pneumococcal Infections* / drug therapy
  • Pneumococcal Infections* / epidemiology
  • Pneumococcal Infections* / microbiology
  • Pneumococcal Vaccines
  • Risk Factors
  • Serogroup
  • Serotyping
  • Streptococcus pneumoniae

Substances

  • Ceftriaxone
  • Penicillins
  • Anti-Infective Agents
  • Anti-Bacterial Agents
  • Pneumococcal Vaccines